HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kirkman Curcumin, Mytrol 300: Health And Wellness New Products Roundup

This article was originally published in The Rose Sheet

Executive Summary

Kirkman offers bioavailable of curcumin its new Curcumin/Turmeric Root Extract; German natural cold/cough remedy Myrtol 300 and Australian sunscreen Solar D launch in US; and more news in brief.

You may also be interested in...



Skin Care Line First For New Chapter Founder Schulick, Nutraceuticals In 2020

New Chapter founder Paul Schulick will introduce skin masks, cleansers and lotions with Algatech's topical astaxanthin to maintain skin microbiome. He also plans to launch nutraceuticals once a non-compete agreement with P&G, the owner of his former firm New Chapter, expires in 2020.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel